<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974296</url>
  </required_header>
  <id_info>
    <org_study_id>7159</org_study_id>
    <nct_id>NCT02974296</nct_id>
  </id_info>
  <brief_title>Neuroimaging in Patients Undergoing TMS for Depression</brief_title>
  <acronym>NIPUTFD</acronym>
  <official_title>Neuroimaging in Patients Undergoing TMS for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to guide rTMS using functional magnetic resonance imaging (fMRI)&#xD;
      in individuals with depression who did not respond to standard TMS treatment to evaluate&#xD;
      whether targeted TMS using individualized functional MRI scans produce outcome superior to&#xD;
      that of conventional approaches. The study team also plans to scan patients with Major&#xD;
      Depression Disorder (MDD) patients prescribed to receive standard TMS for the first time&#xD;
      before and after which they will have resting-state Functional Magnetic Resonance Imaging&#xD;
      (rs-FMRI) scan in order to see if we can predict their responsiveness based on the functional&#xD;
      connectivity maps.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Significance: There are few therapeutic options for individuals with treatment resistant&#xD;
      depression (TRD). One recently developed approach is rTMS over left dorsolateral prefrontal&#xD;
      cortex. Recent studies have demonstrated overall antidepressant benefit of rTMS in patients&#xD;
      who fail to respond to a trial of antidepressant medication (1, 2, 3). Nevertheless, for many&#xD;
      patients the response is incomplete, suggesting the need for further optimization. One&#xD;
      potential cause of heterogeneous response might relate to individual differences in brain&#xD;
      anatomy and connectivity patterns. At present, the rTMS stimulation site across subjects is&#xD;
      based upon fixed location relative to motor cortex. Potentially, however, the approach could&#xD;
      be optimized by stimulating based upon individual brain functional connectivity pattern. The&#xD;
      present project will collect pre- and post-treatment brain functional connectivity measures&#xD;
      in a group of patients who will be receiving independent clinical rTMS for resistant&#xD;
      depression, a connectivity-based targeting approach will be applied at the single-subject&#xD;
      level to individualize therapy in those patients who do not respond to standard approaches.&#xD;
&#xD;
      Patients will be divided in 2 groups. Group 1 (N=30) will be depressed patients undergoing&#xD;
      standard TMS for the first time. Group 2 (N=30) constitutes those who have previously&#xD;
      demonstrated that they do not respond to standard TMS. MDD patients prescribed to receive&#xD;
      standard TMS for the first time (group 1) will have resting-state FMRI in order to see if&#xD;
      their responsiveness based on the functional connectivity maps can be predicted.&#xD;
      Non-responders to standard TMS approaches (Group 2) will be randomized (3:2) to either&#xD;
      receive targeted (N=18) or standard (N=12) repetitive TMS (rTMS) treatments. A&#xD;
      connectivity-based targeting strategy will be used on patients undergoing targeted rTMS to&#xD;
      optimize target for focal brain stimulation. Raters and patients in group 2 will be kept&#xD;
      blinded to the treatment assignment. All patients referred from the ongoing treatment study&#xD;
      will be assessed by 3 tesla brain MRI, Magnetic Resonance Spectroscopy (MRS) and Cerebral&#xD;
      Blood Flow/Volume (CBF/CBV) procedures at baseline and immediately following the final&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2017</start_date>
  <completion_date type="Actual">August 20, 2019</completion_date>
  <primary_completion_date type="Actual">August 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Functional Connectivity Measured by Resting MRI</measure>
    <time_frame>Week 1 prior to first TMS treatment and week 36 after completion of TMS treatments</time_frame>
    <description>Change from Baseline in Resting MRI Correlation Coefficients Between Left Dorsolateral Prefrontal Cortex and Subgenual Anterior Cingulate Change in Resting MRI is defined as post-pre</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Depressive Symptoms Measured by the Hamilton Depression Rating Scale (17-item HDRS)</measure>
    <time_frame>Week 1 prior to first TMS treatment and week 36 after completion of TMS treatments</time_frame>
    <description>Patients will be classified as responders to TMS with at least 50% decrease in HDRS scores from baseline. Patients will be classified as non-responders to TMS with less than 50% decrease in HDRS scores from baseline.&#xD;
Change in HDRS-17 scores is defined as: [pre-post)/pre]x100 HDRS-17 scores range: 0-61&#xD;
Levels of depression based on HDRS-17 scores:&#xD;
Not depressed: 0-7 Mild (subthreshold): 8-13 Moderate (mild): 14-18 Severe (moderate): 19-22 Very severe (severe): &gt;23</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>new target TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>new target transcranial magnetic stimulation guided by MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard TMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard transcranial magnetic stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial magnetic stimulation</intervention_name>
    <description>non invasive brain stimulation approach</description>
    <arm_group_label>new target TMS</arm_group_label>
    <arm_group_label>standard TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          1. Male or female outpatients, 18 to 60 years of age.&#xD;
&#xD;
          2. Primary diagnosis of Major Depressive Disorder as confirmed by the Structured Clinical&#xD;
             Interview for Diagnostic and Statistical Manual (DSM-IV-TR) Disorders (SCID-IV-TR).&#xD;
&#xD;
          3. Duration of the index episode of at least 1 month.&#xD;
&#xD;
          4. MDD symptoms, defined as a total HDRS-17 score â‰¥ 18 despite treatment with an adequate&#xD;
             trial of a serotonin reuptake inhibitor (SRI).&#xD;
&#xD;
          5. Individuals who cannot tolerate medications.&#xD;
&#xD;
          6. Patients currently on medication must be at the same stable dose(s) for 1 month prior&#xD;
             to enrollment and be willing to continue at the same dose(s) through the duration of&#xD;
             the study.&#xD;
&#xD;
          7. Capable and willing to provide informed consent.&#xD;
&#xD;
          8. Signed HIPAA authorization.&#xD;
&#xD;
          9. Right-handed.&#xD;
&#xD;
         10. Willingness to undergo research fMRI scan (3T).&#xD;
&#xD;
         11. Willingness to undergo randomization to either treatment arm.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. Investigators, and their immediate families (defined as a spouse, parent, child or&#xD;
             sibling, whether by birth or legal adoption).&#xD;
&#xD;
          2. Individuals diagnosed by the investigators with the following conditions: Bipolar&#xD;
             Disorder (lifetime), any Psychotic Disorder (lifetime), history of substance abuse or&#xD;
             dependence within the past year (except nicotine and caffeine).&#xD;
&#xD;
          3. Behavior, which in the judgment of the investigator may hinder the patient in&#xD;
             completing the procedures required by the study protocol.&#xD;
&#xD;
          4. Individuals with a clinically defined neurological disorder including, but not limited&#xD;
             to: tics, space occupying brain lesion; any history of seizures except those&#xD;
             therapeutically induced by electroconvulsive therapy (ECT); history of cerebrovascular&#xD;
             accident; history of fainting; transient ischemic attack within two years; cerebral&#xD;
             aneurysm, Dementia; Parkinson's Disease; Huntington chorea; Multiple Sclerosis.&#xD;
&#xD;
          5. Increased risk of seizure for any reason, including prior diagnosis of increased&#xD;
             intracranial pressure (such as after large infarctions or trauma), or history of&#xD;
             significant head trauma with loss of consciousness for â‰¥ 5 minutes.&#xD;
&#xD;
          6. Use of any investigational drug within 12 weeks of the randomization visit.&#xD;
&#xD;
          7. Significant acute suicide risk, defined as follow: suicide attempt within the previous&#xD;
             6 months that required medical treatment; or â‰¥ 2 suicide attempts in the past 12&#xD;
             months; or in the investigator's opinion, has significant risk for suicide based on&#xD;
             the current state or recent history.&#xD;
&#xD;
          8. Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable&#xD;
             cardiac disease.&#xD;
&#xD;
          9. Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants,&#xD;
             or electrodes) or any other metal object within or near the head, excluding the mouth,&#xD;
             that cannot be safely removed.&#xD;
&#xD;
         10. Current illicit drug use (cannabinoid, phencyclidine, amphetamines, barbiturates,&#xD;
             cocaine, methadone, and opiates), defined as drug use during the 6 months before&#xD;
             screening.&#xD;
&#xD;
         11. Known or suspected pregnancy. Urine pregnancy test Women who are breast-feeding.&#xD;
&#xD;
         12. Women of childbearing potential not using a medically accepted form of contraception&#xD;
             when engaging in sexual intercourse.&#xD;
&#xD;
         13. Medicinal patch, unless removed prior to the magnetic resonance (MR) scan.&#xD;
&#xD;
         14. MDD patients with very severe depression, defined as a total HDRS-17 score â‰¥ 23, will&#xD;
             be excluded and referred to immediate treatment.&#xD;
&#xD;
         15. Risks related to seizures, such as substance abuse or sleep disruptions/insomnia.&#xD;
&#xD;
        SpecificExclusion criteria (group 1):&#xD;
&#xD;
        History of treatment with rTMS therapy for any disorder.&#xD;
&#xD;
        Specific Inclusion criteria (group 2):&#xD;
&#xD;
        History of non-response to rTMS in this depressive episode.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C. Javitt, MD Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>New York State Psychiatric Institute &amp; Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moreno-Ortega M, Kangarlu A, Lee S, Perera T, Kangarlu J, Palomo T, Glasser MF, Javitt DC. Parcel-guided rTMS for depression. Transl Psychiatry. 2020 Aug 12;10(1):283. doi: 10.1038/s41398-020-00970-8.</citation>
    <PMID>32788580</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <results_first_submitted>September 9, 2020</results_first_submitted>
  <results_first_submitted_qc>October 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2020</results_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Marta Moreno Ortega, PHD</investigator_full_name>
    <investigator_title>Associate Research Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02974296/Prot_ICF_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02974296/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>New Target TMS</title>
          <description>new target transcranial magnetic stimulation guided by MRI&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
        </group>
        <group group_id="P2">
          <title>Standard TMS</title>
          <description>standard transcranial magnetic stimulation&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Target TMS</title>
          <description>new target transcranial magnetic stimulation guided by MRI&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
        </group>
        <group group_id="B2">
          <title>Standard TMS</title>
          <description>standard transcranial magnetic stimulation&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.70" spread="16.028"/>
                    <measurement group_id="B2" value="41.50" spread="15.152"/>
                    <measurement group_id="B3" value="40.21" spread="15.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Functional Connectivity Measured by Resting MRI</title>
        <description>Change from Baseline in Resting MRI Correlation Coefficients Between Left Dorsolateral Prefrontal Cortex and Subgenual Anterior Cingulate Change in Resting MRI is defined as post-pre</description>
        <time_frame>Week 1 prior to first TMS treatment and week 36 after completion of TMS treatments</time_frame>
        <group_list>
          <group group_id="O1">
            <title>New Target TMS</title>
            <description>new target transcranial magnetic stimulation guided by MRI&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
          </group>
          <group group_id="O2">
            <title>Standard TMS</title>
            <description>standard transcranial magnetic stimulation&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Connectivity Measured by Resting MRI</title>
          <description>Change from Baseline in Resting MRI Correlation Coefficients Between Left Dorsolateral Prefrontal Cortex and Subgenual Anterior Cingulate Change in Resting MRI is defined as post-pre</description>
          <units>correlation coefficients</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103399365" spread="0.161565183"/>
                    <measurement group_id="O2" value="-0.7637409" spread="0.106948404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depressive Symptoms Measured by the Hamilton Depression Rating Scale (17-item HDRS)</title>
        <description>Patients will be classified as responders to TMS with at least 50% decrease in HDRS scores from baseline. Patients will be classified as non-responders to TMS with less than 50% decrease in HDRS scores from baseline.&#xD;
Change in HDRS-17 scores is defined as: [pre-post)/pre]x100 HDRS-17 scores range: 0-61&#xD;
Levels of depression based on HDRS-17 scores:&#xD;
Not depressed: 0-7 Mild (subthreshold): 8-13 Moderate (mild): 14-18 Severe (moderate): 19-22 Very severe (severe): &gt;23</description>
        <time_frame>Week 1 prior to first TMS treatment and week 36 after completion of TMS treatments</time_frame>
        <group_list>
          <group group_id="O1">
            <title>New Target TMS</title>
            <description>new target transcranial magnetic stimulation guided by MRI&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
          </group>
          <group group_id="O2">
            <title>Standard TMS</title>
            <description>standard transcranial magnetic stimulation&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depressive Symptoms Measured by the Hamilton Depression Rating Scale (17-item HDRS)</title>
          <description>Patients will be classified as responders to TMS with at least 50% decrease in HDRS scores from baseline. Patients will be classified as non-responders to TMS with less than 50% decrease in HDRS scores from baseline.&#xD;
Change in HDRS-17 scores is defined as: [pre-post)/pre]x100 HDRS-17 scores range: 0-61&#xD;
Levels of depression based on HDRS-17 scores:&#xD;
Not depressed: 0-7 Mild (subthreshold): 8-13 Moderate (mild): 14-18 Severe (moderate): 19-22 Very severe (severe): &gt;23</description>
          <units>percentage change in HDRS scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9440" spread="15.16426"/>
                    <measurement group_id="O2" value="27.7345" spread="27.48549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>New Target TMS</title>
          <description>new target transcranial magnetic stimulation guided by MRI&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
        </group>
        <group group_id="E2">
          <title>Standard TMS</title>
          <description>standard transcranial magnetic stimulation&#xD;
transcranial magnetic stimulation: non invasive brain stimulation approach</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DR. Marta Moreno-Ortega</name_or_title>
      <organization>Columbia University</organization>
      <phone>9142187311</phone>
      <email>mm4355@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

